https://scholars.lib.ntu.edu.tw/handle/123456789/518325
標題: | Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma | 作者: | RUEY-LONG HONG Ting L.-L. JENG-YUH KO Hsu M.-M. Sheen T.-S. PEI-JEN LOU CHIA-CHUN WANG Chung N.-N. Lui L.T. |
公開日期: | 2001 | 出版社: | Lippincott Williams and Wilkins | 卷: | 19 | 期: | 23 | 起(迄)頁: | 4305-4313 | 來源出版物: | Journal of Clinical Oncology | 摘要: | Purpose: Survival in advanced nasopharyngeal carcinoma (NPC) is compromised by distant metastasis. Because mitomycin is active against hypoxic and GO cells, which may help to eradicate micrometastasis, we investigated the effect of mitomycin-containing cisplatin-based induction chemotherapy. Patients and Methods: Recruited for this study were American Joint Committee on Cancer (AJCC) 1992 staging system stage IV NPC patients with the following adverse features: obvious intracranial invasion, supra-clavicular or bilateral neck lymph node metastasis, large neck node (> 6 cm), or elevated serum lactate dehydrogenase (LDH) level. Patients were given three cycles of chemotherapy before radiotherapy. The chemotherapy comprised a 3-week cycle of mitomycin, epirubicin, and cisplatin on day 1 and fluorouracil and leucovorin on day 8 (MEPFL). Results: From January 1994 to December 1997, 111 patients were recruited. The median follow-up period was 43 months. The actuarial 5-year overall survival rate was 70% (95% confidence interval [CI], 60% to 80%; n = 111). For patients having completed radiotherapy (n = 100), the 5-year locoregional control rate was 70% (95% CI, 55% to 84%) and the distant metastasis-free rate was 81% (95% CI, 73% to 89%). The 5-year distant metastasis-free rate of N3a and N3b disease of AJCC 1997 staging system were 79% (95% CI, 62% to 95%) and 74% (95% CI, 60% to 89%), respectively. By Cox multivariate analysis, high pre-treatment serum LDH level (P = .04) and neck nodal enlargement before radiotherapy (P = .001) were adverse prognostic factors of survival. Conclusion: The good 5-year survival of N3 disease supports the effectiveness of induction MEPFL in the primary treatment of advanced NPC. Further investigation to incorporate concurrent chemoradiotherapy is warranted. ? 2001 by American Society of Clinical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035576411&doi=10.1200%2fJCO.2001.19.23.4305&partnerID=40&md5=c3dfda19b08e764b15af661907ceb76c https://scholars.lib.ntu.edu.tw/handle/123456789/518325 |
ISSN: | 0732-183X | DOI: | 10.1200/JCO.2001.19.23.4305 | SDG/關鍵字: | cisplatin; epirubicin; fluorouracil; folinic acid; mitomycin; adult; aged; alopecia; article; cancer combination chemotherapy; cancer invasion; cancer radiotherapy; cancer survival; drug effect; female; human; infection; leukopenia; liver toxicity; lymph node metastasis; major clinical study; male; nasopharynx carcinoma; nausea; nephrotoxicity; priority journal; thrombocytopenia; vomiting |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。